Glox Therapeutics, a developer of precision antibiotic therapies based on naturally occurring bacteriocins, has been awarded £500,000 from Collaborative Discovery Program (CDP) launched by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate and LifeArc. Glox Therapeutics will work to accelerate the development of its precision antibiotics to address the growing need for effective treatments to overcome antimicrobial-resistant lung infections in people with cystic fibrosis (CF).

Glox Therapeutics’ protein bacteriocin engineering platform allows for the development of potent therapeutics that selectively eradicate drug-resistant pathogenic bacteria. These antibiotics are designed to work without damaging the human microbiome.

The CF AMR Syndicate combines the expertise of leaders in CF and AMR from industry, academia and the clinic, with insights from people living with CF to accelerate CF antimicrobial drug discovery and development. This collaborative approach will allow Glox Therapeutics to benefit from expert support and resources to help expedite the discovery and development of new and effective treatment options for people with CF lung infections.

Dr. James Clark, CEO and Co-founder, Glox Therapeutics, said, “There is a critical need for new and effective therapeutics to tackle the rise of antimicrobial-resistant lung infections in people with CF. We are grateful to LifeArc for the CDP funding, recognizing the potential of Glox Therapeutics’ unique platform to address this urgent unmet need. The collaborative support, disease insights and expert guidance of the CF AMR Syndicate will be incredibly valuable as we advance the development of our precision antibiotics to help improve the lives of patients.”